#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Pneumonia Idiopathic inflammatory myopathy Endocrine ophthalmopathy Systemic candida Immune-mediated myositis Activated PI3 kinase delta syndrome Mycobacterium abscessus infection Necrotising myositis Transient ischaemic attack Mixed-type liposarcoma Colitis ulcerative Type IIa hyperlipidaemia Primary mediastinal large B-cell lymphoma Oesophageal squamous cell carcinoma Systemic mastocytosis More trials…

    Learn about Rare Diseases

    Congenital hypotransferrinaemia – Trials in Disease Retinitis pigmentosa – Life with Disease Paraneoplastic neurological syndrome – Treatment Congenital hypotransferrinaemia Mast cell activation syndrome – Diagnostics Waldenstrom’s macroglobulinaemia recurrent – Trials in Disease Acquired haemophilia – Life with Disease Lysosomal storage disorder – Diagnostics Synovial sarcoma recurrent – Life with Disease Antithrombin III deficiency – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Crd-4730 Brepocitinib Tosilate Siplizumab Fampridine Belzupacap Sarotalocan Amoxicillin Ttx-030 Milvexian Macrogol 4000 LINAPRAZAN GLURATE Gemlapodect Surzebiclimab Bay 3283142 Deferoxamine Delafloxacin Placebo Human Fibrinogen Benzocaine GSKVX000000034792 AGA2118 More therapies…

    Learn about Your Condition

    Acquired haemophilia Eructation Follicular lymphoma stage III Hyperhidrosis Salivary gland cancer Malignant melanoma stage III Thyroidectomy Peripheral artery thrombosis Menopausal symptoms Systemic scleroderma Hodgkin's disease recurrent Angiosarcoma metastatic Mitochondrial DNA depletion Rhabdomyosarcoma Colorectal cancer More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Somogy Varmegyei Kaposi Mor Oktato Korhaz

Somogy Varmegyei Kaposi Mor Oktato Korhaz

Tallian Gyula Utca 20-32, Kaposvar, 7400, Hungary

Want to learn more about this study or check if you can participate? Contact us.

  • A Study of Zenagamtide in Adults With Overweight or Obesity and Type 2 Diabetes

    Recruiting

    3 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    • Obesity
    • Overweight
    Croatia Hungary Italy Romania Slovakia

  • A study of PF-08634404 and a drug combination in adults with advanced or metastatic non-small cell lung cancer

    Recruiting

    3 1 1
    Investigated Drugs:
    • Carboplatin
    • Paclitaxel
    • Paclitaxel Albumin-Bound
    Czechia France Germany Greece Hungary Italy +2

  • Study of Sotorasib, Panitumumab and a drug combination for patients with metastatic colorectal cancer with KRAS p.G12C mutation.

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Colorectal cancer metastatic
    Investigated Drugs:
    • Panitumumab
    • Sotorasib
    • Bevacizumab
    Austria Belgium Bulgaria Czechia Denmark Estonia +12

  • Study of Ziftomenib with drug combinations for adults with newly diagnosed acute myeloid leukemia with NPM1 or KMT2A genetic changes

    Recruiting

    3 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • Daunorubicin Hydrochloride
    • Ziftomenib
    • Azacitidine
    Belgium Czechia France Germany Greece Hungary +4

  • A study testing how well AZD4144 works and how safe it is for adults with acute kidney injury caused by sepsis

    Recruiting

    2 1
    Investigated Diseases:
    • Acute kidney injury
    Belgium Czechia Denmark France Germany Greece +3

  • A study of RO7268489 added to ocrelizumab compared to placebo in adults with progressive multiple sclerosis

    Recruiting

    2 1 1
    Investigated Diseases:
    • Multiple sclerosis
    Investigated Drugs:
    • RO7268489
    • Ocrelizumab
    France Germany Hungary Italy Poland Portugal +1

  • Study of oral rilzabrutinib for adults with immune thrombocytopenia who did not respond to first-line treatment

    Recruiting

    3 1 1
    Investigated Diseases:
    • Immune thrombocytopenia
    Investigated Drugs:
    • Rilzabrutinib
    Austria Czechia France Germany Hungary Italy +3

  • Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

    Recruiting

    3 1 1
    Investigated Diseases:
    • Cardiovascular disorder
    • Hypertension
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Bi 690517
    • Empagliflozin
    Austria Belgium Bulgaria Croatia Czechia Denmark +17

  • Study of Seladelpar Treatment in Patients with Primary Biliary Cholangitis and Compensated Cirrhosis

    Recruiting

    3 1
    Investigated Drugs:
    • Seladelpar
    Austria Belgium Czechia Denmark France Germany +7

  • Study of Sigvotatug Vedotin and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • SIGVOTATUG VEDOTIN
    • Pembrolizumab
    Austria Belgium Bulgaria Czechia Denmark France +9
1 2 3 … 12
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!